We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Doric Nimrod Air One Limited | LSE:DNA | London | Ordinary Share | GG00B4MF3899 | ORD PRF SHS NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 60.00 | 59.00 | 61.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Swiss drugmaker Roche Holding AG (ROG.VX) said Thursday it has agreed with Genentech Inc. (DNA) to buy the 44% of the U.S. biotech company that it doesn't already own for around $46.8 billion.
Roche, based in Basel, said it expects the transaction to be accretive to earnings in the first year after closing.
The agreement ends a nearly eight month battle, in which Genentech repeatedly rejected Roche's offer.
Last Friday, Roche increased the offer price to $93 a share. The agreement reached now is for a slightly higher price of $95 a share.
"We believe this is a fair offer for Genentech shareholders," said Charles Sanders, chairman of a special committee of independent Genentech board members in a statement. "We look forward to working with Roche to complete the transaction as expeditiously as possible."
Company Web site: www.roche.com
-By Anita Greil, of Dow Jones Newswires; +41 43 443 8044; anita.greil@dowjones.com
1 Year Doric Nimrod Air One Chart |
1 Month Doric Nimrod Air One Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions